No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 17 of the 38 quarters in the window, leaving 21 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 868.2x · 10Y median 33.3x · 89th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 39
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:01:16.485Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T14:01:16.485Z. Latest historical point 2022-02-28. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T14:01:16.485Z. Latest historical point 2022-02-28. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T14:01:16.485Z. Latest historical point 2022-02-28. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T14:01:16.485Z. Latest historical point 2022-02-28.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T14:01:16.485Z. Latest historical point 2022-02-28. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:01:16.485Z. Latest historical point 2022-02-28. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:01:16.485Z. Latest historical point 2022-02-28. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Denali Therapeutics Inc. (DNLI) stock was $19.72 as of Oct 6, 2026, 10:00 AM EDT, down 0.98% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +29.0% · 3-year avg -2.0%/yr · 5-year avg -16.9%/yr
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States.
Biotechnology · South San Francisco, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2020-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.37
Revenue Est.
$12.22M
Last Quarter Results
EPS
$-0.68
vs Estimate
$-0.47
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1DNLI | $3.13B | $19.71 | -0.98% | +28.96% | -16.91% | N/A | N/A |
| 2ARQT | $3.14B | $25.07 | -0.32% | +26.11% | -0.28% | N/A | vs DNLI |
| 3ELVN | $3.11B | $43.60 | -4.12% | +130.94% | +24.57% | N/A | vs DNLI |
| 4AMLX | $3.08B | $27.66 | -0.43% | +106.29% | N/A | N/A | vs DNLI |
| 5TMDX | $2.85B | $82.48 | -0.61% | -28.15% | +21.77% | N/A | vs DNLI |
| 6DYN | $2.84B | $15.21 | -1.52% | +18.13% | -0.38% | N/A | vs DNLI |
forward FY estimate
N/A
$3.60M
vs Estimate
$2.15M
Consensus Rating
Based on 16 analysts
Average Price Target
$36.06
+82.9% upside
Low
$27.00
Current
$19.71
High
$42.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.49 | $-0.37 | $-0.30 | 13 |
| Quarter ending Dec 2026 | $-0.76 | $-0.63 | $-0.48 | 13 |
| Quarter ending Mar 2027 | $-2.21 | $-0.62 | $-0.21 | 5 |
| Quarter ending Jun 2027 | $-2.24 | $-0.62 | $-0.21 | 5 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.36 | $-2.29 | $-2.18 | 15 |
| FY 2027 | $-2.60 | $-2.35 | $-1.86 | 16 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $10.28M | $12.22M | $24.37M | 13 |
| Quarter ending Dec 2026 | $12.36M | $22.71M | $65.79M | 13 |
| Quarter ending Mar 2027 | $11.02M | $22.27M | $66.55M | 6 |
| Quarter ending Jun 2027 | $12.62M | $25.51M | $76.24M | 6 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $25.06M | $38.97M | $89.80M | 15 |
| FY 2027 | $88.95M | $130.36M | $226.53M | 15 |
